Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 2 , Pages 331-340 , April 2008

Maximal androgen blockade for advanced prostate cancer

  • Laurence Klotz, MD (Professor of Surgery)

      Affiliations

    • Corresponding Author InformationTel.: +1 416 480 4673; Fax: +1 416 480 6121.

References 

  1. Labrie F, Dupont A, Belanger A, et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an anti-androgen. Clinical and Investigative Medicine. 1982;5(4):267–275
  2. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nature Medicine. 2004 Jan;10(1):33–39
  3. Partin A, Coffey D. In:  Walsh P editors. Campbell's urology. 7th edn.. Philadelphia: WB Saunders; 1998;p. 1399
  4. Kuil CW, Berrevoets CA, Mulder E. Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. Studies on the mechanism of antiandrogen action. The Journal of Biological Chemistry. 1995;270:27569–27576
  5. Culig Z. Androgen receptor cross-talk with cell signalling pathways. Growth Factors. 2004 Sep;22(3):179–184
  6. Hodgson MC, Astapova I, Hollenberg AN, et al. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Research. 2007 Sep 1;67(17):8388–8395
  7. Hu X, Lazar MA. Transcriptional repression by nuclear hormone receptors. Trends in Endocrinology and Metabolism. 2000;11:6–10
  8. Bouchal J, Baumforth KR, Sváchová M, et al. Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines. The Journal of Pharmacy and Pharmacology. 2005 Jan;57(1):83–92
  9. Gottlieb B, Vasiliou DM, Lumbroso R, et al. Analysis of exon 1 mutations in the androgen receptor gene. Human Mutation. 1999;14:527–539
  10. Culig Z, Hoffmann J, Erdel M, et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. British Journal of Cancer. 1999;81:242–251
  11. Kolvenbag GJCM, Furr BJA, Blackledge GRP. Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity. Prostate Cancer and Proststic Diseases. 1998;1:307–314
  12. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. The New England Journal of Medicine. 1998;339(15):1036–1042
  13. McLeod DG. Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. The Oncologist. 1997;2:18–27
  14. Schellhammer PF, Sharifi R, Block NL, et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final results of a multicentre, double-blind, randomized trial. British Journal of Urology. 1997;80:278
  15. Titus MA, Schell MJ, Lih FB, et al. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clinical Cancer Research. 2005 Jul 1;11(13):4653–4657
  16. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. The Journal of Urology. 1993 Mar;149(3):607–609
  17. Small EJ, Srinivas S. The anti androgen withdrawal syndrome: experience in a large cohort of unselected patients with advanced prostate cancer. Cancer. 2005;76:1428–3418
  18. Fuse H, Korenaga S, Sakari M, et al. Non-steroidal antiandrogens act as AF-1 agonists under conditions of high androgen-receptor expression. The Prostate. 2007 May 1;67(6):630–637
  19. Bohl CE, Gao W, Miller DD, et al. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 2005 Apr 26;102(17):6201–6206
  20. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. The New England Journal of Medicine. 1989;321:419–424
  21. Klotz L. Combined androgen blockade in prostate cancer: meta-analyses and associated issues. BJU International. 2001;87:806–813
  22. Prostate Cancer Trialists' Collaborative Group . Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000;355:1491–1498
  23. Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer. 2002;95:361–376
  24. Agency for Health Care Policy and Research . Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment for advanced prostatic cancer. Available from: http://www.ahcpr.gov/clinic/tp/prostp.htm[accessed 27 01 04]
  25. Klotz LH, Newman T. Does maximal androgen blockade (MAB) improve survival? A critical appraisal of the evidence. The Canadian Journal of Urology. 1996 Sep;3(3):246–250
  26. Bennett CL, Tosteson TD, Schmitt B, et al. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer Prostatic Diseases. 1999 Jan;2(1):4–8
  27. Klotz L, Schellhammer P, Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU International. 2004 Jun;93(9):1177–1182
  28. Rothmann M, Li N, Chen G, et al. Design and analysis of non-inferiority mortality trials in oncology. Statistics in Medicine. 2003;22:239–264
  29. Fisher LD, Gent M, Buller HR. Active control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin and placebo. American Heart Journal. 2001;141:26–32
  30. Usami M, Akaza H, Arai Y, et al. Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. Prostate Cancer Prostatic Diseases. 2007;10(2):194–201
  31. Moinpour CM, Savage MJ, Troxel A, et al. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. Journal of the National Cancer Institute. 1998 Oct 21;90(20):1537–1544
  32. Yamada Y, Takahashi S, Fujimura T, et al. The effect of combined androgen blockade on bone turnover and bone mineral density in men with prostate cancer. Osteoporosis International. 2008 Mar;19(3):321–327[Epub 2007 Sep 29]
  33. Penson D, Ramsay S, Veenstra D, et al. The cost effectiveness of combined androgen blockade with bicalutamide and LHRH agonist in men with metastatic prostate cancer. The Journal of Urology. 2005;174(2):547–552
  34. Aprikian AG, Fleshner N, Langleben A, et al. An oncology perspective on the benefits and cost of combined androgen blockade in advanced prostate cancer. The Canadian Journal of Urology. 2003;10:1986–1994
  35. Freedland SJ, Humphreys EB, Mangold LA, et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. Journal of Clinical Oncology. 2007 May 1;25(13):1765–1771
  36. Kassouf W, Tanguay S, Aprikian AG. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. The Journal of Urology. 2003;169:1742–1744
  37. Akaza H, Usami M et al. Updated results of the Japanese Bicalutamide Trial. Presented at the European Multidisciplinary Uro-Oncology Conference, Barcelona, Nov 2007.

PII: S1521-690X(08)00005-5

doi: 10.1016/j.beem.2008.01.004

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 2 , Pages 331-340 , April 2008

Article Tools